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Abstract
Objective: To describe a protocol that was based on an integrative neurobiological model of scientific investigation to better understand the 
pathophysiology of obsessive-compulsive disorder and to present the clinical and demographic characteristics of the sample. Method: A standardized 
research protocol that combines different methods of investigation (genetics, neuropsychology, morphometric magnetic resonance imaging and 
molecular neuroimaging of the dopamine transporter) obtained before and after treatment of drug-naïve adult obsessive-compulsive disorder 
patients submitted to a sequentially allocated 12-week clinical trial with a selective serotonin reuptake inhibitor (fluoxetine) and group cognitive-
behavioral therapy. Results: Fifty-two treatment-naïve obsessive-compulsive disorder patients entered the clinical trial (27 received fluoxetine 
and 25 received group cognitive-behavioral therapy). At baseline, 47 blood samples for genetic studies, 50 neuropsychological evaluations, 50 
morphometrical magnetic resonance images and 48 TRODAT-1 single-photon emission computed tomography (SPECT) exams were obtained. 
After 12 weeks, 38 patients completed the protocol (fluoxetine = 20 and GCBT = 18). Thirty-eight neuropsychological evaluations, 31 
morphometrical magnetic resonance images and 34 TRODAT-1 SPECT exams were obtained post-treatment. Forty-one healthy controls matched 
for age, gender, socioeconomic status, level of education and laterality were submitted to the same research procedures at baseline. Conclusion: 
The comprehensive treatment response protocol applied in this project allowing integration on genetic, neuropsychological, morphometrical and 
molecular imaging of the dopamine transporter data in drug-naïve patients has the potential to generate important original information on the 
neurobiology of obsessive-compulsive disorder, and at the same time be clinically meaningful.
Descriptors: Obsessive-compulsive disorder; Genetics; Cognition; Imaging; Treatment outcome
Resumo
Objetivo: Descrever um protocolo integrativo de investigação neurobiológica para melhor compreender as bases patofisiológicas do 
transtorno obsessivo-compulsivo e apresentar as características clínicas e demográficas da amostra. Método: Protocolo padronizado 
que combina diferentes modalidades de investigação (genética, neuropsicologia, ressonância magnética cerebral e imagem molecular 
do transportador de dopamina) obtidas antes e depois do tratamento em pacientes com transtorno obsessivo-compulsivo nunca 
expostos à medicação submetidos a um ensaio clínico comparando um inibidor seletivo da recaptação de serotonina (fluoxetina) e 
terapia cognitivo-comportamental em grupo. Resultados: Cinquenta e dois pacientes com transtorno obsessivo-compulsivo entraram 
no ensaio clínico (27 no grupo fluoxetina e 25 no grupo de terapia). No início, foram realizadas 47 coletas de sangue para genética, 
50 avaliações neuropsicológicas, 50 ressonâncias magnéticas cerebrais e 48 exames de tomografia computadorizada por emissão 
de fóton único (SPECT) com TRODAT-1. Depois de 12 semanas, 38 pacientes terminaram o protocolo (20 no grupo de fluoxetina e 
18 no grupo de terapia). Trinta e oito reavaliações neuropsicológicas, 31 ressonâncias magnéticas de crânio e 34 exames de SPECT 
foram obtidos após o tratamento. Quarenta e um controles pareados foram submetidos ao mesmo protocolo inicial. Conclusão: Os 
dados genéticos, neuropsicológicos, volumétricos e moleculares do transportador de dopamina aliados à resposta a tratamento podem 
tanto gerar informações importantes a respeito da neurobiologia do transtorno obsessivo-compulsivo quanto ter uma aplicação clínica.
Descritores: Transtorno obsessivo-compulsivo; Genética; Neuroimagem; Cognição; Resultados de tratamento
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Introduction
Obsessive-compulsive disorder (OCD) has been considered one of 
the most robust and reliable models supporting pathological brain 
alterations amongst psychiatric disorders.1 However, in contrast 
to the growing evidence of a biological basis for OCD, there is 
still limited knowledge regarding its etiology, patterns of cognitive 
functioning and neurochemical mechanisms.2
New genetic and neuroimaging techniques, such as genome wide 
scans, structural and functional magnetic resonance imaging (MRI), 
as well as molecular imaging single photon emission computed 
tomography (SPECT) and positron emission tomography (PET)3 
are important tools that can help to clarify the pathophysiology of 
OCD. Such knowledge will allow the identification of individuals at 
early risk for OCD, the development of novel treatment strategies, 
as well as the ability to predict response to different interventions.4
Twin and family studies have shown the importance of genetic 
factors for the expression of OCD. Most molecular genetics 
research has focused on genes encoding neurotransmitters of the 
serotoninergic, dopaminergic and glutamatergic systems but, except 
for the glutamate transporter gene,5 the results have not been 
replicated yet. Serotoninergic and dopaminergic molecular imaging 
studies have also been conducted to evaluate these systems in OCD, 
with positive6 and negative results.7,8
The lack of specific trait markers involved in OCD may be related 
to several potentially confounding  factors, including  heterogeneous 
clinical presentation,9 high rates of comorbidity,9 age of onset10 and 
the effects of exposure to previous treatments (pharmacological and/
or psychotherapeutic) on neural circuits.1,11 
In addition, a critical issue that limits identification of biological 
markers for OCD is the small number of controlled longitudinal 
studies comparing brain alterations following different interventions. 
The comparison of different treatments’ effects on the brain by 
means of longitudinal studies would be important for several reasons. 
First, longitudinal studies allow for measuring brain alterations 
following a certain intervention. Secondly, since cognitive-behavioral 
therapy (CBT) and serotonin reuptake inhibitors have proven to 
be as efficacious as pharmacological treatment in reducing OCD 
symptoms,12 it is crucial to understand their neural mechanisms 
of action, neurobiological commonalities and differences between 
them, improving the search for novel treatment strategies. Thirdly, 
such an approach would provide further information to support 
clinical decision-making based on neurobiological predictors’ 
patterns, resulting in improved individual patient care.
In this context, the main objective of this manuscript is to 
describe a standardized research protocol with broad inclusion 
criteria that combines different methods of investigation (genetics, 
neuropsychology, structural MRI and molecular neuroimaging of the 
dopamine transporter) performed before and after treatment of drug-
naïve adult OCD outpatients. These outpatients were submitted to a 
12-week clinical trial where they were sequentially allocated either to 
treatment with a selective serotonin reuptake inhibitor (fluoxetine) or 
group cognitive-behavioral therapy (GCBT). This study investigates 
the hypothesis that this integrative protocol will provide valid and 
original information to better understand the pathophysiology of 
OCD, and, at the same time, be clinically meaningful (Figure 1, 
adapted from Linden, 2006).13 
Moreover, we describe the demographic and clinical characteristics 
of the sample collected in this study and compare these results with 
previously published data from 630 patients collected from the 
Brazilian Research Consortium on Obsessive-Compulsive Spectrum 
Disorders,14 in order to investigate their generalizability.
Method
All participants were informed about the research procedures and 
signed an informed consent submitted and approved by the Local 
Ethics Committee (Universidade de São Paulo, Universidade Federal 
de São Paulo, and Hospital Israelita Albert Einstein).
This research is part of a larger clinical trial15,16 conducted in our 
outpatient clinic (The Obsessive-Compulsive Spectrum Disorders 
Program – PROTOC) specializing in OCD at the Department & 
Institute of Psychiatry,  Universidade de São Paulo. The primary 
objective of this trial was to compare, in a setting closer to clinical 
practice, the clinical effectiveness of SSRI (fluoxetine) and GCBT 
treatments.
1. Sample selection
Patients were referred from primary psychiatric services, from the 
Brazilian Association of Tourette Syndrome and OCD - ASTOC (www.
astoc.org.br), or were recruited through the local media (radio, TV, 
newspapers, internet).
Healthy controls were recruited among college students, hospital 
and university staff, or were obtained through word of mouth.
Patients interested in the treatment study went through an initial 
psychopathological screening by telephone. This first interview 
was conducted by an experienced psychologist who explained 
the treatment protocol and obtained an initial gross evaluation of 
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obsessive-compulsive symptoms and checked for major inclusion/
exclusion criteria. If the subject met the initial basic requirements, 
a clinical psychiatric appointment was scheduled.
Healthy controls also underwent a psychopathological screening 
by telephone, performed by the same psychologist. The purpose 
of this screening was to exclude subjects presenting psychiatric 
symptoms or contraindications which would prevent them from 
undergoing the neuroimaging and neuropsychological research 
procedures. Controls who met the initial requirements were 
scheduled for a clinical evaluation, made on the basis of structured 
interviews (“Assessment Package”, described below).
After the telephone screening, the selected patients were 
interviewed by psychiatrists at the OCD outpatient clinic performing 
the first psychiatric evaluation before enrollment. This interview 
included: 1) Clinical and psychiatric medical assessment; 
2) Structured Clinical Interview screening for DSM-IV Axis I Disorders 
3) Physical examination; 4) Electrocardiogram and general blood 
tests (hemogram, liver and kidney functions, blood glucose levels, 
electrolytes, thyroid hormones).
Inclusion criteria for this protocol were as follows: 1) age between 
18-65 years; 2) to present a primary DSM-IV diagnosis of OCD; 
3) Y-BOCS score ≥ 16 for obsessions and compulsions or ≥ 10 
only for obsessions or compulsions.
Exclusion criteria were: 1) previous exposure to any kind 
of psychotropic medication (benzodiazepines, antipsychotics, 
antidepressants, stimulants, mood stabilizers); 2) previous exposure 
to at least 12 sessions of CBT; 3) any condition that could impair 
the interpretation of results (e.g., a history of skull-brain trauma 
with post-traumatic amnesia); 4) past or current drug abuse or 
dependence;  5) past or current history of psychotic symptoms; 
6) suicide risk; 7) any significant systemic illness or unstable 
medical condition; 8) any significant neurological disease.
Inclusion and exclusion criteria for healthy controls were the same, 
except for the presence of psychiatric disorders.
2. Assessment instruments
From eligible patients, an “Assessment Package” was obtained 
before the treatment allocation process. More details about this 
Assessment Package and instrument references may be found 
elsewhere.14 This assessment was also obtained from healthy 
controls after the telephone screening.
Briefly, this package includes: informed consent form, medical 
history, socio-demographic data, ABIPEME rating scale (a Brazilian 
scale used to determine socio-economic status), semi-structured 
interview on family psychiatric history, structured clinical interview 
for DSM-IV (SCID-I) and additional modules for tic and impulse 
control disorders, attention deficit hyperactivity disorder (ADHD) 
and separation anxiety modules of the Kiddie Schedule for Affective 
Disorders and Schizophrenia (K-SADS), Yale-Brown Obsessive-
Compulsive Scale (Y-BOCS), Dimensional Yale-Brown Obsessive-
Compulsive Scale (DYBOCS), Yale Global Tic Severity Scale 
(YGTSS), Beck Depression (BDI) and Anxiety (BAI) Inventories, 
Universidade de São Paulo Sensory Phenomena Scale (USP-SPS), 
Brown Assessment of Beliefs Scale (BABS); Social Assessment Scale 
(SAS); Brazilian version of the Medical Outcomes Study Short Form 
36 (SF-36);  Clinical Global Impressions Scale (CGI).
3. Allocation to treatment groups
A computer program was developed to sequentially allocate 
patients,17 in which prognostic factors such as initial Y-BOCS 
score, gender, age, and previous treatment history were inserted 
to calculate the smallest difference of these characteristics between 
treatment groups. The aim of this method was to minimize possible 
differences between groups by balancing for possible confounders 
in a clinical trial that evaluates treatment efficacy.17
The allocation process was conducted for each three patients 
recruited, with two patients allocated to GCBT and one to medication, 
or vice-versa, according to the necessity of composing treatment 
groups at each time. Allocation for each group was determined 
blindly without the knowledge of the professionals responsible for 
screening, recruiting and following patients. Therefore, there was 
no possibility of manipulating the insertion of a specific patient into 
any of the treatments.17
4. Treatments
Participants were sequentially allocated to one of the two groups 
of treatment: SSRI (fluoxetine) or GCBT.
1) SSRI treatment15
Patients allocated to pharmacological treatment received fluoxetine 
(up to 80mg/day) for 12 weeks, starting at 20mg/day in the first 
week, with weekly increases of 20mg/day. Medical appointments 
were scheduled every four weeks. At the first consultation, 
patients received a detailed explanation about the delayed onset of 
therapeutic effects and potential drug side effects. Intolerable side 
effects were managed by reducing the dosage and, if they persisted 
at the subsequent consultation, a second SSRI (preferentially 
sertraline) would be used.
Intermediate scores evaluations (Y-BOCS and CGI) at weeks 4 and 
8 were obtained by the psychiatrist responsible for the treatment of 
each patient (not blinded).
2) GCBT treatment16
Patients allocated to GCBT were divided into subgroups of 6-8 
patients each and attended a weekly 2-h session during twelve 
weeks. The protocol emphasized exercises of exposure and response 
prevention (EX/RP) and cognitive techniques, such as correction of 
thoughts and beliefs, and relapse prevention strategies. Patients 
who missed more than two consecutive sessions were considered 
drop-outs.
Intermediate scores evaluations (Y-BOCS and CGI) at sessions 
4 and 8 were obtained by the psychologist responsible for the 
treatment of each patient (not blinded).
3) Outcome measures for treatment improvement
After completing 12 weeks of SSRI or GCBT treatment, the 
following measurements were obtained by a rater blinded to the 
treatment condition: Y-BOCS, DYBOCS, BDI, BAI, SAS, SF-36 
and CGI.
Treatment response was calculated as a continuous variable 
(percent reduction in baseline Y-BOCS score) and as a categorical 
variable (or ≥ 35% reduction in baseline Y-BOCS score). Patients 
presenting a ≥ 35% reduction in baseline Y-BOCS score and a CGI 
score of 1 (much better) or 2 (better) were considered responders. 
5. Database
All assessments were checked for quality assurance. The whole 
package was inserted into the database via SPSS Builder (electronic 
mask).
6. Genetic, cognitive and imaging assessments
All drug naïve patients enrolled in the clinical trial described 
above were invited to participate in the imaging, genetic and 
cognitive controlled study. For those who were willing to participate, 
a complete explanation of all the procedures and flowcharts was 
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given, as summarized in Figure 1. The same sort of explanation 
was given to the healthy controls recruited for this study. Briefly, 
the procedures were: blood sample collection for genetics studies, 
neuropsychological assessment for the cognitive controlled study, 
structural MRI for the volumetric study and SPECT-TRODAT-1 for the 
dopamine transporter study. These procedures were performed at 
baseline for patients and controls. After treatment, patients repeated 
all these procedures, except for blood sample collection. Whenever 
possible, a second neuropsychological assessment and MRI exams 
were obtained from the controls. SPECT-TRODAT-1 evaluation was 
not obtained again from controls due to ethical issues.
Patients and normal controls were strongly encouraged to 
participate in the whole protocol, but there were situations where 
this was not possible such as meeting exclusion criteria for a specific 
procedure (pacemaker for MRI, for example) or refusing to undergo 
a specific procedure
1) Blood samples for the genetic studies
Venous blood samples were collected in three tubes of 5ml with 
anticoagulant (EDTA). Genomic DNA was extracted from peripheral 
blood leukocytes of the patients and controls using the salting-out 
method.18 The quality and quantity of the DNA were checked 
by A260/A280 using a Nanodrop spectrophotometer (Nanodrop 
Technologies, CA).  All DNA samples were stored in a freezer at -80 
°C for future genetics studies. More specifically, a variable number 
of tandem repeats in the 3’ untranslated region of the dopamine 
transporter (SLC6A3) will be investigated for association with in 
vivo striatal dopamine transporter availability.
2) Neuropychological assessment 
A neuropsychological assessment was performed by trained 
neuropsychologists in a session lasting approximately three hours 
(Table 1). The application of neuropsychological tests followed a 
fixed order of presentation, and those that require more concentration 
were undertaken early in the session for being more susceptible to 
fatigue. The correction was made by a neuropsychologist “blind” to 
the type of treatment received. Patients and controls were excluded 
if they presented learning disabilities such as dyslexia, dyscalculia 
or dysgraphia.
3) Structural MRI for the morphometric study
Images were acquired using a 1.5 T GE Signa scanner (General 
Electric, Milwaukee WI, USA). Contiguous 1.6 mm axial images 
across the entire brain were acquired, using a T1-3D SPGR 
sequence providing 248 contiguous slices, voxel size = 0.94mm 
× 0.94mm × 0.80mm, TE = 4.20 ms, TR = 10.5ms, flip 
angle = 15, acquisition matrix = 256 × 192.
Patients and controls were not eligible for MRI study if they 
presented a history of significant head trauma followed by loss 
of consciousness or had known structural brain abnormalities. 
Claustrophobia, presence of pacemakers, aneurysm clips, artificial 
heart valves, and ear implants, metal fragments or foreign objects 
in the eyes, skin or body were also impeditive.
4) SPECT of the dopamine transporter for the molecular imaging study
SPECT scans were performed with [Tc99m]-TRODAT-1, a 
radiotracer with high selectivity and specificity for the dopamine 
transporter. TRODAT-1 kits were produced by the Institute of Nuclear 
Energy Research (INER-Taiwan R.O.C.) and labeled according to 
Choi et al.35 Images were acquired four hours after the injection 
of 740 MBq (20mCi) of [Tc99m]-TRODAT-1 using a Dual-head 
gamma camera “Hawk Eye” (General Electric Medical System, 
USA), equipped with high-resolution fan beam collimators. For each 
scan a total of 128 projections (30s per frame) were collected in a 
step-and-shoot mode on circular 360° orbit in a 128x128 matrix 
with the mean radius of rotation of 15.5cm.36
The image data were reconstructed by standard filtered back 
projection using a Butterworth filter (cut-off frequency 0.45) with 
attenuations by Chang’s method.
Patients and controls were not eligible for SPECT if they were 
allergic to chemicals in the radioactive tracer, or were pregnant or 
breast-feeding.
7. Statistical analyses
To describe the demographic and clinical characteristics of the 
sample, the Mann-Whitney test was used to compare numerical 
variables, whereas the Chi-square test was used for categorical 
variables. The Chi-square test with Yates’ continuity correction was 
used when fewer than 5 patients were analyzed for a given variable. 
All statistical tests were interpreted with 5% level of significance.
Results
1. Sample enrollment
Figure 2 depicts the enrollment, allocation, follow-up and data 
acquisition from patients and controls.
Six hundred and twenty-three preliminary telephone screenings 
of patients were performed from the beginning of 2006 to the end 
of 2008. Three hundred and sixty nine potential OCD subjects 
were then evaluated by the psychiatric team. Of these, 78 (21.1%) 
were drug naïve, but only 52 participated in this protocol and were 
sequentially allocated as follows: 27 to SSRI (fluoxetine) (51.9%) 
and 25 to GCBT (48.1%).
Fifty four potential healthy controls were screened by telephone 
from the beginning of 2006 to the end of 2008 and 44 (81.5%) were 
eligible for the study, but only 41 were enrolled in the protocol because 3 
screened controls declined to participate prior to the procedures. Reasons 
for ineligibility were: 1 potential control had past head trauma followed 
by a loss of consciousness, 3 controls had psychiatric disorders screened 
by the SCID, 1 control had a significant family history of depression, 
1 control had past use of amphetamines to lose weight, 1 had taken 
bupropion, 2 did not have the appropriate level of education required 
and 1 declined after reading the protocol.
After 12 weeks of treatment, 38 of the 52 drug naïve patients 
(73.1%) finished the protocol. Of those, 20 belonged to the 
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sexual/religious. Patients were also more impaired than controls in 
terms of their professional activity (p = 0.05).
As also expected, given the relatively broad inclusion criteria of the 
study, the patients’ comorbidity profile was also diverse (Table 3). 
Generalized anxiety disorder, major depression, social phobia and 
simple phobia were the most prevalent comorbidities, found both 
for current and lifetime status investigation. Lifetime presence of 
obsessive compulsive spectrum disorders, such as body dysmorphic 
disorder, hypochondria, Tourette syndrome, trichotillomania and 
somatization disorder represented 15% or less of the sample.
Drug-Naïve OCD patients versus OCD Consortium patients
Table 4 shows the main clinical and sociodemographic 
characteristics of the drug-naïve OCD patients in comparison to 
the Brazilian OCD Consortium patients. No statistically significant 
differences were found in the sociodemographic characteristics or 
OCS content, except for age, illness duration, “other” symptom 
dimensions (miscellaneous dimension), depression (BDI) and 
anxiety (BAI) scores and, obviously, for previous psychiatric 
treatment. Drug-naïve patients were younger, had shorter illness 
duration, had higher depression and anxiety scores, more 
miscellaneous symptoms and had never experienced psychiatric 
treatment. Eighteen (34.6%) of the drug-naïve patients had been 
submitted to psychotherapy, but just two patients had received CBT 
in the past. The lifetime Axis I psychiatric comorbidities comparison 
did not differ statistically between drug-naïve and consortium 
OCD patients. 
Discussion
This paper describes a standardized research protocol which 
aims to generate information in order to establish an integrative 
model for the scientific investigation of the pathophysiology of OCD 
fluoxetine group and 18 to the GCBT. Dropout rates were 25.9% 
in the SSRI group (n = 7) and 28% in the GCBT (n = 7) 
(p = 0.87). The main reasons related to discontinuation/not 
initiation of treatment in the fluoxetine group were: 2 patients failed 
to initiate treatment due to allocation dissatisfaction, 3 patients 
reported lack of time to comply with scheduled consultations, 1 
patient had side effects and stopped taking the medication of their 
own accord, and 1 patient missed a consultation and had to stop 
taking the medication. Among patients in GCBT, the reasons for 
treatment discontinuation were: 2 patients did not come for the 
initial consultation, 1 patient stopped the treatment due to allocation 
dissatisfaction, 1 patient missed the last therapy session and did not 
complete the outcome instruments, 2 patients stopped the treatment 
due to improvement of symptoms after some sessions and 1 patient 
had to start antidepressants due to depressive symptoms.
Sixteen neuropsychological assessments were also performed on 
controls after 12 weeks and 9 MRI exams were acquired after a 
period varying from 10 to 18 months.
2. Sample characteristics
Baseline demographic and clinical characteristics of patients and 
controls enrolled in the study are shown in Table 2. The groups 
were balanced for age, gender, level of education, socioeconomic 
status and handedness. The mean age of obsessive-compulsive 
symptoms onset was 12.9 (S.E. = 1.04) years and 17.8 
(S.E. = 1.36) years had passed from the first symptom onset. 
Patients had a mean Y-BOCS score of 25.5 (S.E. = 0.69) points. 
As predicted, there were statistically significant differences between 
the groups on measures of obsessive-compulsive symptom 
dimensions, depression and anxiety severities. Among patients, 
the commonest symptom dimension was symmetry/ordering, 
following by aggression, contamination/cleaning, hoarding and 
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In order to achieve reliable neurobiological comparisons, 
drug-naïve patients and healthy controls were well characterized 
phenotypically, and were matched for the mainly socio-
demographic characteristics such as age, gender, level of 
education, socioeconomic status and handedness (Table 2). 
Additionally, as a result of the allocation process, the number 
of patients allocated to SSRI (51.9%) or GCBT (48.1%) was 
similar.  Following the interventions, there were no differences 
in the dropout rates for each intervention (28% for GCBT versus 
25.9% for SSRI). These rates were similar to those found in 
a recent study from our group evaluating abandonment rates 
among OCD patients (drug-naïve and non-drug-naïve patients) 
enrolled in the larger clinical trial during two years of follow up 
(Diniz et al., unpublished observations).
An interesting point to be addressed is whether the OCD drug 
naïve patients would have different clinical and socio-demographic 
characteristics from previously treated patients that sought treatment 
at our service. To address this question, we compared the clinical and 
demographic characteristics of the present sample with data from 
630 OCD patients studied by the Brazilian Research Consortium 
on Obsessive-Compulsive Spectrum Disorders14 (Table 4). 
As expected, the preliminary comparisons showed that drug-naïve 
patients were younger and had shorter illness duration. Additionally, 
they presented more symptoms from the miscellaneous dimension. 
Interestingly, they presented the same age at onset and the same 
time gap before starting treatment. This similarity in profile may 
have occurred as a result of our close relationship with the Brazilian 
Association of Patients with OCD and TS (ASTOC); due to our robust 
recruitment process, or because it is not common for primary and 
and secondly to be clinically meaningful (Figure 1). In addition, it 
depicted the demographic and clinical characteristics of the present 
sample comparing these results with previously collected data from 
630 patients from the Brazilian Research Consortium on Obsessive-
Compulsive Spectrum Disorders.14
The present protocol involved blood sample collection for genetic 
studies and assessment of several clinical and neurobiological 
(neuropsychology, structural MRI, SPECT of the dopamine 
transporter) measures before and after two standardized treatments 
(pharmacotherapy and psychotherapy) in a relatively large and rare 
sample of adult OCD patients who had never been exposed to any 
psychotropic medication or CBT (Figure 2). 
Hoexter MQ et al.351
Rev Bras Psiquiatr. 2009;31(4):345-53
secondary health services in our city to offer specialized treatment 
for OCD. The long delay before seeking treatment observed in drug 
naïve and consortium patients reinforces the concept that OCD is 
a hidden disorder, in which patients are secretive and embarrassed 
about their symptoms.37 Patients in the drug naïve group had 
slightly higher depression and anxiety scores. The slightly better 
scores in depression and anxiety scales of the consortium patients 
could reflect the fact that the majority of these patients (75%) were 
already in treatment when the assessments were made.14 Of note, 
the severity of obsessive-compulsive symptoms measured by the 
Y-BOCS was similar for both groups, as well as the comorbidity and 
symptom dimension profiles. 
Though the comorbid axis I conditions observed in this study are 
similar to the profile reported in most OCD clinical investigations,14 
in which comorbid major depressive disorder and anxiety disorders 
in general are highly frequent, and despite the fact that the core 
features of OCD are relatively alike worldwide,38 our results cannot 
be directly generalized to the overall OCD population given our 
specific effort to investigate drug naïve patients.
This study has some limitations. Firstly, not all patients and 
controls were submitted to all the investigation procedures. In 
addition, given the broad inclusion criteria adopted to build a setting 
closer to clinical practice, many comorbidities were not excluded. 
Although broader inclusion criteria lead to study samples more likely 
to represent a real population,39 this approach has the disadvantage 
of including too many comorbidities which may confuse the 
interpretation of neurobiological findings.
Finally, genetic, cognitive and imaging studies are extremely 
relevant to understanding the neurobiology of mental disorders. 
Future studies with larger sample sizes are necessary to increase 
the statistical power of the neurobiological measures. In this sense, 
the establishment of collaborative multicenter neuroimaging and 
neuropsychological protocols is essential, with the ultimate goal of 
developing more individualized treatments.
In conclusion, this study has many important methodological 
strengths, which will give credibility for its future findings in genetic, 
neuropsychological and imaging studies. First, a large sample of 
OCD drug-naïve patients was included. Second, this is a longitudinal 
study in which the clinical sample was allocated to two different 
modalities of intervention proven to be effective in reducing obsessive-
compulsive symptoms. Third, patients and healthy controls were 
matched and well characterized phenotypically. Fourth, given the 
complexity of mental disorders, an approach integrating different 
modalities of investigation (genetic, phenomenology, neuroimaging 
and neuropsychology) with a treatment intervention may represent 
a more powerful tool for understanding the neurobiology of OCD 
and at the same time its clinical relevance. Lastly, the comparison 
of this sample with a national sample suggests that the clinical 
features of the present drug-naïve OCD sample are representative 
of the general OCD population.
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